Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.48 |
| ▸ | ACACB | O00763 | 2/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.45 |
| ▸ | FPR1 | P21462 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | TEK | Q02763 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749850 | 1.00 | NR1H4 (0.49) | NR1H4MCHR1ACACBDGAT1FPR1 | |
| SCHEMBL12528785 | 0.96 | MCHR1 (0.47) | NR1H4MCHR1ACACBDGAT1FPR1 | |
| SCHEMBL12532130 | 0.89 | MAPT (0.50) | NR1H4MCHR1 | |
| SCHEMBL1750594 | 0.87 | MCHR1 (0.53) | NR1H4MCHR1DGAT1 | |
| SCHEMBL1750596 | 0.87 | MCHR1 (0.53) | NR1H4MCHR1DGAT1 | |
| SCHEMBL12528780 | 0.87 | RAB9A (0.54) | HTT | |
| SCHEMBL1750191 | 0.85 | MCHR1 (0.55) | MCHR1FPR1FPR2WDR5HTT | |
| SCHEMBL1750189 | 0.85 | MCHR1 (0.55) | MCHR1FPR1FPR2WDR5HTT | |
| SCHEMBL1749130 | 0.84 | MCHR1 (0.54) | MCHR1FPR1FPR2WDR5HTT | |
| SCHEMBL1749132 | 0.84 | MCHR1 (0.54) | MCHR1FPR1FPR2WDR5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | NR1H4 269/4885MCHR1 1838/4885ACACB 4048/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | NR1H4 277/4885MCHR1 2068/4885ACACB 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.